IIIHIIII USOO5583242A United States Patent (19) 11 Patent Number: 5,583,242 Schieven (45) Date of Patent: Dec
Total Page:16
File Type:pdf, Size:1020Kb
IIIHIIII USOO5583242A United States Patent (19) 11 Patent Number: 5,583,242 Schieven (45) Date of Patent: Dec. 10, 1996 54 USE OF PHOSPHOTYROSINE L. B. Justement et al., "Regulation of B Cell Antigen PHOSPHATASE INHIBITORS FOR Receptor Signal Transduction and Phosphorylation by CONTROLLING CELLULAR CD45,” Science 252:1839-1842 (1991). PROLFERATION M. R. Gold et al., "Stimulation of Protein Tyrosine Phos phorylation by the B-Lymphocyte Antigen Receptor,' 75 Inventor: Gary L. Schieven, Seattle, Wash. Nature 345.810-813 (1990). M. C. Cam et al., “In Vivo Antidiabetic Actions of Naglivan, 73) Assignee: Bristol-Myers Squibb Company, New An Organic Vanadyl Compound in Streptozotocin-Induced York, N.Y. Diabetes, Diabetes Res. & Clin. Pract. 20:111-121 (1993). A. L. Burkhardt et al., "Anti-Immunoglobulin Stimulation (21) Appl. No.: 450,342 of B Lymphocytes Activates src-Related Protein-Tyrosine Kinases.' Proc. Natl. Acad. Sci. USA 88:7410–7414 (1991). 22 Filed: May 25, 1995 F. M. Uckun et al., “Tyrosine Phosphorylation Is a Manda tory Proximal Step in Radiation-Induced Activation of the Related U.S. Application Data Protein Kinase C Signaling Pathway in Human B-Lympho cyte Precursors,” Proc. Natl. Acad. Sci. USA 90:252-256 62 Division of Ser. No. 189,330, Jan. 31, 1994. (1993). (51 Int. Cl. ........................................ C07F 5/00 C. P. Stewart & A. L. Prote, "Electron Paramagnetic Reso (52 U.S. Cl. ................................... 556/44; 556/1; 556/42; nance Spectra of Some Oxovanadium (IV) Chelates,” J. 556/114: 556/116; 556/17 Chem. Soc. Dalton Trans. 1661-1666 (1972). 58) Field of Search .................................... 556/1, 42, 44, X.-R. Yao & D. W. Scott, “Expression of Protein Tyrosine Kinases in the Ig Complex of Anti-I-Sensitive and 556/114, 116, 117 Anti-I-Resistant B-Cell Lymphomas: Role of the p55' 56) References Cited Kinase in Signaling Growth Arrest and Apoptosis,' Immu nol. Rev. 132:163-186 (1993). U.S. PATENT DOCUMENTS X.-R. Yao & D. W. Scott, "Antisense Oligodeoxynucle 5,023,358 6/1991 Lazaro et al. ............................. 556/42 otides to the blkTyrosine Kinase Prevent Anti-I-Chain-Me 5,175,001 12/1992 Lazaro et al. ........................... 424/451 diated Growth Inhibition and Apoptosis in a B-Cell Lyn phoma.” Proc. Natl. Acad. Sci. USA 90:7946-7950 (1993). OTHER PUBLICATIONS F. M. Uckun et al., "Ionizing Radiation Stimulates Uniden tified Tyrosine-Specific Protein Kinases in Human B-Lym G. J. V. Nossal, "Cellular Mechanisms of Immunologic phocyte Precursors, Triggering Apoptosis and Clonogenic Tolerance.' Annu. Rev. Immunol. 1:33-62 (1983). Cell Death.' Proc. Natl. Acad. Sci. USA 89:9005-9009 F. M. Uckun & J. A. Ledbetter, "Immunobiologic Differ (1992). ences Between Normal and Leukemic Human Cell Precur P. J. L. Lane et al., "The Role of Tyrosine Phosphorylation sors.' Proc. Natl. Acad. Sci., USA 85:8603-8607 (1988). in Signal Transduction Through Surface Ig in Human B T. R. Burke et al., “Preparation of Fluoro-and Hydroxy-4-(Phosphonomethyl)-D.L-Phenylalanine Suit Cells,” J. Immunol. 146:715-722 (1991). ably Protected for Solid-Phase Synthesis of Peptides Con (List continued on next page.) taining Hydrolytically Stable Analogues of O-Phosphoty rosine,” J. Org. Chem. 58:1336–1340 (1993). Primary Examiner-Porfirio Nazario-Gonzales D. B. A. de Bont et al., "Solid-Phase Synthesis of O-Phos Attorney, Agent, or Firm-Merchant, Gould, Smith, Edell, phorothioylserine-and-Threonine-Containing Peptides as Welter & Schmidt Well as of O-Phosphoserine- and - Threonine-Containing 57 ABSTRACT Peptides,” J. Org. Chem. 58:1309-1317 (1993). K. Guan et al., "ATyr/Ser Protein Phosphatase Encoded by A method of inhibiting the proliferation of B cells by using Vaccinia Virus,' Nature 350:359-362 (1991). inhibitors of phosphotyrosine phosphatase can be used to regulate the immune response and to treat diseases such as D. Dailey et al., “Novel Yeast Protein Kinase (YPK1 Gene leukemias or lymphomas marked by malignant proliferation Product) Is A 40-Kilodalton Phosphotyrosyl Protein Asso of B cells. The use of such inhibitors can be combined with ciated with Protein-Tyrosine Kinase Activity, Mol. Cell. radiation, which produces a synergistic effect. Several types Biol. 10:6244-6256 (1990). of inhibitors can be used, including: (1) compounds com M. Imoto et al., “Dephostatin, a Novel Protein Tyrosine prising a metal coordinate-covalently bound to an organic Phosphatase Inhibitor Produced by Streptomyces. I. Tax moiety that can form a five- or six-membered ring; (2) onomy, Isolation, and Characterization,” J. Antibiotics compounds in which vanadium (IV) is coordinate-co 46:1342-1346 (1993). valently bound to an organic moiety such as a hydroxamate, J. H. McNeill et al., "Bis(maltolato)oxovanadium (IV) Is a O-hydroxypyridinone, O-hydroxypyrone, O-amino acid, Potent Insulin Mimic,” J. Med. Chem. 35:1489-1491 hydroxycarbonyl, or thiohydroxamate; (3) coordinate-cova (1992). lent complexes of vanadyl and cysteine or a derivative R. R. Bartlett et al., "Leflunomide (HWA 486), a Novel thereof; (4) nonhydrolyzable phosphotyrosine phosphatase Immunomodulating Compound for the Treatment of analogues; (5) phostatin; and (6) 4-(fluoromethyl)phenyl Autoimmune Disorders and Reactions Leading to Trans phosphate and esterified derivatives. For the metal-contain plantation Rejection,” Agents & Actions 32:10-21 (1991). ing coordinate covalent compounds, the metal is preferably J. K. Myers & T. S. Widlanski, "Mechanism-Based Inacti vanadium (IV). vation of Prostatic Acid Phosphatase,” Science 262:1451-1453 (1993). 5 Claims, 12 Drawing Sheets 5,583,242 Page 2 OTHER PUBLICATIONS Abstract of a presentation made at the Ninth International Symposium on Cellular Endocrinology: "Cell Signalling F. M. Uckun et al., "Use of a Novel Colony Assay to and the Molecular Stress Response', Lake Placid, New Evaluate the Cytotoxicity of an Immunotoxin Containing York, Sep. 23–26, 1993, by G. L. Schieven et al., entitled Pokeweed Antiviral Protein Against Blast Progenitor Cells Identification of Reactive Oxygen Intermediate Responsive Freshly Obtained from Patients with Common B-Lineage Tyrosine Kinases in Lymphocytes. Acute Lymphoblastic Leukemia,” J. Exp. Med. 163:347-368 (1986). A. Shaver et al., "Insulin-Mimetic Peroxovanadium Com M-A. Campbell & B. M. Sefton, "Protein Tyrosine Phos plexes: Preparation and Structure of Potassium Oxodiperoxo phorylation is Induced in Murine B Lymphocytes in (pyridine-2-carboxylato) vanadate (V), K. Response to Stimulation with Anti-Immunoglobulin,' VO(O)(CHNCOO)12H2O, and Potassium Oxidiper EMBO J. 9:2125-2131 (1990). oxo (3-hydroxypyridine-2-carboxylato) vanadate (V), Abstract of a presentation made at the Annual Meeting of the KVO(O)(OHCHNCOO)3H2O, and Their Reactions Oxygen Society, Charleston, South Carolina, on Nov. with Cysteine,” Inorg. Chem. 32: 3109-3113 (1993). 12-17, 1993, by G. L. Schieven et al., “Identification of J. P. Secrist et al., "Stimulatory Effects of the Protein Reactive Oxygen Intermediate Responsive Tyrosine Kinases Tyrosine Phosphatase Inhibitor, Pervanadate, on T-cell in Lymphocytes.”. Activation Events.' J. Biol. Chem, 268:5886-5893 (1993). U.S. Patent Dec. 10, 1996 Sheet 1 of 12 5,583,242 U.S. Patent Dec. 10, 1996 Sheet 2 of 12 5,583,242 Jaen U.S. Patent Dec. 10, 1996 Sheet 3 of 12 5,583,242 /t/99 U.S. Patent Dec. 10, 1996 Sheet 4 of 12 5,583,242 X) s NOTW839YSOG(Wri) OZOO-ri6çd6+ OOOOOZ 00009! 00000! 00009 U.S. Patent Dec. 10, 1996 Sheet 5 of 12 5,583,242 OZOO-TlOydo-ri+ 09 00092|| OOOOO! ; : 0009Z THYMONE NCORPORATION (CPM) U.S. Patent Dec. 10, 1996 Sheet 6 of 12 5,583,242 §99Z 1.NEWLIVE!!!1 OOOZ 000|| COLONES PER OOOO CEUS U.S. Patent Dec. 10, 1996 Sheet 7 of 12 5,583,242 9 s 3 3 8 O THYMIDNE NCORPORATION (CPM) U.S. Patent Dec. 10, 1996 Sheet 8 of 12 5,583,242 çOO-rigzoo-ri+ AOTW839WSOO COO-(dS) 0009/...! 00009! OO097|| OOOOO! 0009/. 00009 OO092 THYMDINE NCORPORATION CPM U.S. Patent Dec. 10, 1996 Sheet 9 of 12 5,583,242 XKO X XCXXX XXX.& 00000|| 00009 THYMONE NCORPORATION (CPM) U.S. Patent Dec. 10, 1996 Sheet 10 of 12 5,583,242 64992NOTOOWWONIO?!\/O 01OZ02O#OGOz09 NOTW8(Wr!) ’9||-||6 000009 000009 OOOOOZ 00000! SRC ACTMY PHOSPHORIMAGER UNTS U.S. Patent Dec. 10, 1996 Sheet 11 of 12 5,583,242 00900°002 O 009OO;OOZO00°00Z0 (J3GWnNTENNYHO)AJISNGINI3ON3OS38Onl-3 Wri! 249Z:10 24:9:S ×OL:W/Z9 WrdOGwricz Wrio! 00900$00Z O 989, COUNTS (FULL SCALE) U.S. Patent Dec. 10, 1996 Sheet 12 of 12 5,583,242 5,583,242 1. 2 USE OF PHOSPHOTYROSNE treatment of autoimmune diseases such as rheumatoid arthri PHOSPHATASE INHIBITORS FOR tis and lupus erythematosus. CONTROLLING CELLULAR Accordingly, there exists a need for improved methods of PROLFERATION controlling proliferation of B cells in malignant and non malignant conditions without requiring the use of radiation. This is a Divisional of application Ser. No. 08/189,330, Such an approach preferably involves the induction of filed Jan. 31, 1994, now allowed, application(s) are incor programmed cell death (apoptosis) in susceptible cells. porated herein by reference. SUMMARY 10 I have developed a method of inhibiting the proliferation BACKGROUND OF THE INVENTION of B cells by using inhibitors of phosphotyrosine phos This invention is directed to the use of phosphotyrosine phatase. phosphatase inhibitors for controlling cellular proliferation, Several types of inhibitors can be used: particularly proliferation of B lymphocytes. 15 (1) compounds comprising a metal selected from the Tyrosine phosphorylation is known to play an essential group consisting of vanadium (TV), copper (II) and role in the control of lymphocyte function. This control is gallium (II) coordinate-covalently bound to an organic exerted by a network of tyrosine kinases and phosphoty moiety, rosine phosphatases. (2) nonhydrolyzable phosphotyrosine analogs selected Two different processes known to induce B cell apoptosis 20 from the group consisting of N-aryl phosphoramidates, have been shown to act through tyrosine phosphorylation.